The global High Potency API Contract Manufacturing Market garnered a market value of USD 8 Billion in 2022 and is expected to accumulate a market value of USD 16 Billion by registering a CAGR of 7% in the forecast period 2022 to 2032.Because of the rising frequency of cancer cases globally, the usage of HPAPIs is increasing, which is driving the market.
Furthermore, the government is sponsoring therapeutic substance development and research, which is expected to fuel the growth of the high-potency API contract manufacturing market. As a result of the high investment funds required for manufacturing and production facilities, contract product manufacturing is being used. During the forecast period, this will drive the global market.
Increasing demand for pharmaceuticals, a greater emphasis on precision medicine and high-potency APIs, and technological developments in high-potency API production are some of the reasons driving market expansion.
The International Agency for Research on Cancer (IARC) has revised GLOBOCAN 2020 with new cancer burden projections, predicting that the cancer burden would increase to 19.3 million cases and 10 million cancer deaths in 2020. According to this new study, more than 50 million individuals will be diagnosed with cancer within the next five years. The utilization of high-potency API in various medicinal regimens is also contributing to market expansion.
For example, in 2020, the USA Center for Drug Evaluation and Research (CDER) authorized novel medicines for several malignancies, including lung, thyroid, and breast cancer. Small and big API molecules were used in these treatments. These medications' major ingredients are high-potency APIs. With an increasing number of cancer cases, the market for cancer treatment will expand in tandem.
| Data Points | Key Statistics |
|---|---|
| Estimated Base Year Value (2021) | USD 6.5 Billion |
| Expected Market Value (2022) | USD 8 Billion |
| Anticipated Forecast Value (2032) | USD 16 Billion |
| Projected Growth Rate (2022 to 2032) | 7% CAGR |
The global demand for high potency API contract manufacturing is projected to increase at a CAGR of 7% during the forecast period between 2022 and 2032, reaching a total of USD 16 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 5%.
The increased demand for outsourcing HPAPI manufacture, as well as a robust pipeline of targeted therapeutic medications, is projected to drive the growth of the market. However, the concentration of technological expertise in the hands of a few significant companies, as well as the absence of uniform regulatory regulations and standards, are expected to drive the growth of the market.
Other factors driving market expansion include rising demand for antibody-drug conjugates and cancer treatments. Furthermore, the approval of government regulations for the development and manufacture of innovative medicine is expected to boost market growth throughout the forecast period.
Patent Expiration of Blockbuster Drugs to Open New Growth Frontiers
The expiration of patents and subsequent launch of generic versions is a major boon for pharmaceutical businesses to extend their product portfolios and enter attractive market niches in this technology-driven industry.
Several biosimilars have been authorized in Europe, however, the US FDA has only approved one biosimilar yet. Increased research and development operations, as well as ongoing attempts to replicate branded biological medications, would pave the way for the introduction of cost-effective therapeutic options.
Several blockbuster pharmaceuticals are projected to lose their patent protection in the near future, opening up significant prospects in the biosimilar industry. Some of the key medications that will go off patent in the near future are Avastin (bevacizumab), Herceptin (trastuzumab), Synagis (palivizumab), Erbitux (cetuximab), Humira (adalimumab), Remicade (infliximab), and Rituxan (rituximab).
Growing need for Outsourcing HPAPI Manufacturing, as well as a robust pipeline of Targeted Therapeutic Medications
Pharmaceutical firms were hesitant to outsource the production of high-potency APIs; hence the vast bulk of production remained captive or in-house. The fear of patent violation was a major motivator. However, when pharmaceutical businesses began to grow geographically, they began to run out of HPAPIs.
Furthermore, rising medication development and commercialization costs increased the financial strain. With the evolving regulatory and legal environment, outsourcing has proven to be the best alternative for HPAPI manufacture.
The concentration of Technical Expertise across a handful of Players is causing Market Disruption
Manufacturing high-potency APIs is capital-demanding and needs specialized technical know-how; this has been a key obstacle for new players seeking to enter the lucrative HPAPI business. There are now just a few large companies that have established their own capabilities through mergers, acquisitions, collaborations, and Research and Development (R&D).
A host of Medicines in the Pipeline to bolster prospects for API Contract Manufacturing
The Asia Pacific region is predicted to develop at the quickest rate throughout the projection period. The expanding spectrum of prospects, particularly in Japan, China, and India, can be linked to the expansion.
Factors like as a better regulatory environment, a large potential for cost reductions, enhanced risk management skills, and a healthy medication pipeline are projected to boost the region's growth in the coming years. Furthermore, the availability of qualified labor at cheaper prices than in established nations such as the United States is expected to accelerate regional market growth.
Rising Incidence of Illnesses such as Cancer and Neurological Problems to Accelerate Market Growth
During the projection period, North America is likely to have a large market share, estimated at around 38% by 2022-end. With the incidence of illnesses such as cancer and neurological problems, the United States was the most impacted country in the world. As the incidence of these illnesses rises, so will the region's output of HPAPIs.
HPAPIs are frequently employed in cancer and other major diseases therapeutic, drug development, and other research activities. As a result, the demand for the same will be substantially larger in the North American area, where the patient population is growing faster than in other countries. Because of its growing elderly population and increased prevalence and incidence of infectious illnesses, North America is likely to dominate the high-potency APIs/HPAPI market.
Chronic disorders, such as cancer, are also prevalent in the United States. According to the American Cancer Society journal's 2020 report, there will be an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in 2020.
According to the Parkinson's Foundation's 2020 estimates, around 1 million individuals in the United States have Parkinson's disease, which is greater than the total number of persons diagnosed with muscular dystrophy, multiple sclerosis, and Amyotrophic Lateral Sclerosis. By 2030, this figure is predicted to rise to 1.2 million.
Oncology to be a promising Field for High Potency API Contract Manufacturing
According to Future Market Insights, major developments are expected to happen in the oncology segment with regard to high-potency API contract manufacturing. The rising number of cancer cases worldwide is the primary driver of this market. For example,
The Cancer Atlas predicts that there will be 29 million cancer diagnoses by 2040, up from over 18 million in 2018. Furthermore, unlike traditional, systemic treatments, some new cancer medicines in development are exceedingly precise.
Antibody-drug conjugates, which can have occupational exposure levels, and monoclonal antibodies coupled with small molecule cytotoxic chemicals are examples of such targeted HPAPIs. Because of the fast increase of cancer targets, the fraction of HPAPI applications in the therapeutic pipeline is rapidly growing. As per the report, oncology likely accounts for over 63% of all high-potency API contract manufacturing operations.
Demand for Injectables to witness a Steady Incline in Forthcoming Years
The global industry has been subdivided into Injectables, oral solids, lotions, and others based on dosage forms. In 2021, the injectable dosage form sector led the worldwide industry, comprising over 50% of global revenues.
The category is expected to grow at a stable CAGR, maintaining its dominance throughout the projected years. The speedy delivery of HPAPI to the intended area can be credited to the segment's rise. They can be administered subcutaneously (in the fat layer), intradermally (between the layers of skin), or intramuscularly (in the muscle).
Key players in the High Potency API Contract Manufacturing market are Piramal Pharma Solutions, Lonza, Catalent, Inc., VxP Pharma, Inc., Pfizer CentreOne, Gentec Pharmaceutical Group, AbbVie, Aurigene Pharmaceutical Services Ltd., CordenPharma International, and Curia Global, Inc.
Recent Developments:
| Report Attribute | Details |
|---|---|
| Market Value in 2022 | USD 8 Billion |
| Market Value in 2032 | USD 16 Billion |
| Growth Rate | CAGR of 7% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Product Type, Application, Dosage Form, Synthesis, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | The USA, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, China, Japan, South Korea, India, Malaysia, Singapore, Thailand, Australia, New Zealand, GCC, South Africa, Israel |
| Key Companies Profiled | Piramal Pharma Solutions; Lonza; Catalent, Inc.; VxP Pharma, Inc.; Pfizer CentreOne; Gentec Pharmaceutical Group; AbbVie; Aurigene Pharmaceutical Services Ltd.; CordenPharma International; Curia Global, Inc. |
| Customization | Available Upon Request |
Table 1: Global Market Value (US$ million) Forecast by Region, 2017 to 2032
Table 2: Global Market Value (US$ million) Forecast by Product Type, 2017 to 2032
Table 3: Global Market Value (US$ million) Forecast by Synthesis, 2017 to 2032
Table 4: Global Market Value (US$ million) Forecast by Application, 2017 to 2032
Table 5: Global Market Value (US$ million) Forecast by Dosage Form, 2017 to 2032
Table 6: North America Market Value (US$ million) Forecast by Country, 2017 to 2032
Table 7: North America Market Value (US$ million) Forecast by Product Type, 2017 to 2032
Table 8: North America Market Value (US$ million) Forecast by Synthesis, 2017 to 2032
Table 9: North America Market Value (US$ million) Forecast by Application, 2017 to 2032
Table 10: North America Market Value (US$ million) Forecast by Dosage Form, 2017 to 2032
Table 11: Latin America Market Value (US$ million) Forecast by Country, 2017 to 2032
Table 12: Latin America Market Value (US$ million) Forecast by Product Type, 2017 to 2032
Table 13: Latin America Market Value (US$ million) Forecast by Synthesis, 2017 to 2032
Table 14: Latin America Market Value (US$ million) Forecast by Application, 2017 to 2032
Table 15: Latin America Market Value (US$ million) Forecast by Dosage Form, 2017 to 2032
Table 16: Europe Market Value (US$ million) Forecast by Country, 2017 to 2032
Table 17: Europe Market Value (US$ million) Forecast by Product Type, 2017 to 2032
Table 18: Europe Market Value (US$ million) Forecast by Synthesis, 2017 to 2032
Table 19: Europe Market Value (US$ million) Forecast by Application, 2017 to 2032
Table 20: Europe Market Value (US$ million) Forecast by Dosage Form, 2017 to 2032
Table 21: South Asia Market Value (US$ million) Forecast by Country, 2017 to 2032
Table 22: South Asia Market Value (US$ million) Forecast by Product Type, 2017 to 2032
Table 23: South Asia Market Value (US$ million) Forecast by Synthesis, 2017 to 2032
Table 24: South Asia Market Value (US$ million) Forecast by Application, 2017 to 2032
Table 25: South Asia Market Value (US$ million) Forecast by Dosage Form, 2017 to 2032
Table 26: East Asia Market Value (US$ million) Forecast by Country, 2017 to 2032
Table 27: East Asia Market Value (US$ million) Forecast by Product Type, 2017 to 2032
Table 28: East Asia Market Value (US$ million) Forecast by Synthesis, 2017 to 2032
Table 29: East Asia Market Value (US$ million) Forecast by Application, 2017 to 2032
Table 30: East Asia Market Value (US$ million) Forecast by Dosage Form, 2017 to 2032
Table 31: Oceania Market Value (US$ million) Forecast by Country, 2017 to 2032
Table 32: Oceania Market Value (US$ million) Forecast by Product Type, 2017 to 2032
Table 33: Oceania Market Value (US$ million) Forecast by Synthesis, 2017 to 2032
Table 34: Oceania Market Value (US$ million) Forecast by Application, 2017 to 2032
Table 35: Oceania Market Value (US$ million) Forecast by Dosage Form, 2017 to 2032
Table 36: MEA Market Value (US$ million) Forecast by Country, 2017 to 2032
Table 37: MEA Market Value (US$ million) Forecast by Product Type, 2017 to 2032
Table 38: MEA Market Value (US$ million) Forecast by Synthesis, 2017 to 2032
Table 39: MEA Market Value (US$ million) Forecast by Application, 2017 to 2032
Table 40: MEA Market Value (US$ million) Forecast by Dosage Form, 2017 to 2032
Figure 1: Global Market Value (US$ million) by Product Type, 2022 to 2032
Figure 2: Global Market Value (US$ million) by Synthesis, 2022 to 2032
Figure 3: Global Market Value (US$ million) by Application, 2022 to 2032
Figure 4: Global Market Value (US$ million) by Dosage Form, 2022 to 2032
Figure 5: Global Market Value (US$ million) by Region, 2022 to 2032
Figure 6: Global Market Value (US$ million) Analysis by Region, 2017 to 2032
Figure 7: Global Market Value Share (%) and BPS Analysis by Region, 2022 to 2032
Figure 8: Global Market Y-o-Y Growth (%) Projections by Region, 2022 to 2032
Figure 9: Global Market Value (US$ million) Analysis by Product Type, 2017 to 2032
Figure 10: Global Market Value Share (%) and BPS Analysis by Product Type, 2022 to 2032
Figure 11: Global Market Y-o-Y Growth (%) Projections by Product Type, 2022 to 2032
Figure 12: Global Market Value (US$ million) Analysis by Synthesis, 2017 to 2032
Figure 13: Global Market Value Share (%) and BPS Analysis by Synthesis, 2022 to 2032
Figure 14: Global Market Y-o-Y Growth (%) Projections by Synthesis, 2022 to 2032
Figure 15: Global Market Value (US$ million) Analysis by Application, 2017 to 2032
Figure 16: Global Market Value Share (%) and BPS Analysis by Application, 2022 to 2032
Figure 17: Global Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032
Figure 18: Global Market Value (US$ million) Analysis by Dosage Form, 2017 to 2032
Figure 19: Global Market Value Share (%) and BPS Analysis by Dosage Form, 2022 to 2032
Figure 20: Global Market Y-o-Y Growth (%) Projections by Dosage Form, 2022 to 2032
Figure 21: Global Market Attractiveness by Product Type, 2022 to 2032
Figure 22: Global Market Attractiveness by Synthesis, 2022 to 2032
Figure 23: Global Market Attractiveness by Application, 2022 to 2032
Figure 24: Global Market Attractiveness by Dosage Form, 2022 to 2032
Figure 25: Global Market Attractiveness by Region, 2022 to 2032
Figure 26: North America Market Value (US$ million) by Product Type, 2022 to 2032
Figure 27: North America Market Value (US$ million) by Synthesis, 2022 to 2032
Figure 28: North America Market Value (US$ million) by Application, 2022 to 2032
Figure 29: North America Market Value (US$ million) by Dosage Form, 2022 to 2032
Figure 30: North America Market Value (US$ million) by Country, 2022 to 2032
Figure 31: North America Market Value (US$ million) Analysis by Country, 2017 to 2032
Figure 32: North America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 33: North America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 34: North America Market Value (US$ million) Analysis by Product Type, 2017 to 2032
Figure 35: North America Market Value Share (%) and BPS Analysis by Product Type, 2022 to 2032
Figure 36: North America Market Y-o-Y Growth (%) Projections by Product Type, 2022 to 2032
Figure 37: North America Market Value (US$ million) Analysis by Synthesis, 2017 to 2032
Figure 38: North America Market Value Share (%) and BPS Analysis by Synthesis, 2022 to 2032
Figure 39: North America Market Y-o-Y Growth (%) Projections by Synthesis, 2022 to 2032
Figure 40: North America Market Value (US$ million) Analysis by Application, 2017 to 2032
Figure 41: North America Market Value Share (%) and BPS Analysis by Application, 2022 to 2032
Figure 42: North America Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032
Figure 43: North America Market Value (US$ million) Analysis by Dosage Form, 2017 to 2032
Figure 44: North America Market Value Share (%) and BPS Analysis by Dosage Form, 2022 to 2032
Figure 45: North America Market Y-o-Y Growth (%) Projections by Dosage Form, 2022 to 2032
Figure 46: North America Market Attractiveness by Product Type, 2022 to 2032
Figure 47: North America Market Attractiveness by Synthesis, 2022 to 2032
Figure 48: North America Market Attractiveness by Application, 2022 to 2032
Figure 49: North America Market Attractiveness by Dosage Form, 2022 to 2032
Figure 50: North America Market Attractiveness by Country, 2022 to 2032
Figure 51: Latin America Market Value (US$ million) by Product Type, 2022 to 2032
Figure 52: Latin America Market Value (US$ million) by Synthesis, 2022 to 2032
Figure 53: Latin America Market Value (US$ million) by Application, 2022 to 2032
Figure 54: Latin America Market Value (US$ million) by Dosage Form, 2022 to 2032
Figure 55: Latin America Market Value (US$ million) by Country, 2022 to 2032
Figure 56: Latin America Market Value (US$ million) Analysis by Country, 2017 to 2032
Figure 57: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 58: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 59: Latin America Market Value (US$ million) Analysis by Product Type, 2017 to 2032
Figure 60: Latin America Market Value Share (%) and BPS Analysis by Product Type, 2022 to 2032
Figure 61: Latin America Market Y-o-Y Growth (%) Projections by Product Type, 2022 to 2032
Figure 62: Latin America Market Value (US$ million) Analysis by Synthesis, 2017 to 2032
Figure 63: Latin America Market Value Share (%) and BPS Analysis by Synthesis, 2022 to 2032
Figure 64: Latin America Market Y-o-Y Growth (%) Projections by Synthesis, 2022 to 2032
Figure 65: Latin America Market Value (US$ million) Analysis by Application, 2017 to 2032
Figure 66: Latin America Market Value Share (%) and BPS Analysis by Application, 2022 to 2032
Figure 67: Latin America Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032
Figure 68: Latin America Market Value (US$ million) Analysis by Dosage Form, 2017 to 2032
Figure 69: Latin America Market Value Share (%) and BPS Analysis by Dosage Form, 2022 to 2032
Figure 70: Latin America Market Y-o-Y Growth (%) Projections by Dosage Form, 2022 to 2032
Figure 71: Latin America Market Attractiveness by Product Type, 2022 to 2032
Figure 72: Latin America Market Attractiveness by Synthesis, 2022 to 2032
Figure 73: Latin America Market Attractiveness by Application, 2022 to 2032
Figure 74: Latin America Market Attractiveness by Dosage Form, 2022 to 2032
Figure 75: Latin America Market Attractiveness by Country, 2022 to 2032
Figure 76: Europe Market Value (US$ million) by Product Type, 2022 to 2032
Figure 77: Europe Market Value (US$ million) by Synthesis, 2022 to 2032
Figure 78: Europe Market Value (US$ million) by Application, 2022 to 2032
Figure 79: Europe Market Value (US$ million) by Dosage Form, 2022 to 2032
Figure 80: Europe Market Value (US$ million) by Country, 2022 to 2032
Figure 81: Europe Market Value (US$ million) Analysis by Country, 2017 to 2032
Figure 82: Europe Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 83: Europe Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 84: Europe Market Value (US$ million) Analysis by Product Type, 2017 to 2032
Figure 85: Europe Market Value Share (%) and BPS Analysis by Product Type, 2022 to 2032
Figure 86: Europe Market Y-o-Y Growth (%) Projections by Product Type, 2022 to 2032
Figure 87: Europe Market Value (US$ million) Analysis by Synthesis, 2017 to 2032
Figure 88: Europe Market Value Share (%) and BPS Analysis by Synthesis, 2022 to 2032
Figure 89: Europe Market Y-o-Y Growth (%) Projections by Synthesis, 2022 to 2032
Figure 90: Europe Market Value (US$ million) Analysis by Application, 2017 to 2032
Figure 91: Europe Market Value Share (%) and BPS Analysis by Application, 2022 to 2032
Figure 92: Europe Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032
Figure 93: Europe Market Value (US$ million) Analysis by Dosage Form, 2017 to 2032
Figure 94: Europe Market Value Share (%) and BPS Analysis by Dosage Form, 2022 to 2032
Figure 95: Europe Market Y-o-Y Growth (%) Projections by Dosage Form, 2022 to 2032
Figure 96: Europe Market Attractiveness by Product Type, 2022 to 2032
Figure 97: Europe Market Attractiveness by Synthesis, 2022 to 2032
Figure 98: Europe Market Attractiveness by Application, 2022 to 2032
Figure 99: Europe Market Attractiveness by Dosage Form, 2022 to 2032
Figure 100: Europe Market Attractiveness by Country, 2022 to 2032
Figure 101: South Asia Market Value (US$ million) by Product Type, 2022 to 2032
Figure 102: South Asia Market Value (US$ million) by Synthesis, 2022 to 2032
Figure 103: South Asia Market Value (US$ million) by Application, 2022 to 2032
Figure 104: South Asia Market Value (US$ million) by Dosage Form, 2022 to 2032
Figure 105: South Asia Market Value (US$ million) by Country, 2022 to 2032
Figure 106: South Asia Market Value (US$ million) Analysis by Country, 2017 to 2032
Figure 107: South Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 108: South Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 109: South Asia Market Value (US$ million) Analysis by Product Type, 2017 to 2032
Figure 110: South Asia Market Value Share (%) and BPS Analysis by Product Type, 2022 to 2032
Figure 111: South Asia Market Y-o-Y Growth (%) Projections by Product Type, 2022 to 2032
Figure 112: South Asia Market Value (US$ million) Analysis by Synthesis, 2017 to 2032
Figure 113: South Asia Market Value Share (%) and BPS Analysis by Synthesis, 2022 to 2032
Figure 114: South Asia Market Y-o-Y Growth (%) Projections by Synthesis, 2022 to 2032
Figure 115: South Asia Market Value (US$ million) Analysis by Application, 2017 to 2032
Figure 116: South Asia Market Value Share (%) and BPS Analysis by Application, 2022 to 2032
Figure 117: South Asia Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032
Figure 118: South Asia Market Value (US$ million) Analysis by Dosage Form, 2017 to 2032
Figure 119: South Asia Market Value Share (%) and BPS Analysis by Dosage Form, 2022 to 2032
Figure 120: South Asia Market Y-o-Y Growth (%) Projections by Dosage Form, 2022 to 2032
Figure 121: South Asia Market Attractiveness by Product Type, 2022 to 2032
Figure 122: South Asia Market Attractiveness by Synthesis, 2022 to 2032
Figure 123: South Asia Market Attractiveness by Application, 2022 to 2032
Figure 124: South Asia Market Attractiveness by Dosage Form, 2022 to 2032
Figure 125: South Asia Market Attractiveness by Country, 2022 to 2032
Figure 126: East Asia Market Value (US$ million) by Product Type, 2022 to 2032
Figure 127: East Asia Market Value (US$ million) by Synthesis, 2022 to 2032
Figure 128: East Asia Market Value (US$ million) by Application, 2022 to 2032
Figure 129: East Asia Market Value (US$ million) by Dosage Form, 2022 to 2032
Figure 130: East Asia Market Value (US$ million) by Country, 2022 to 2032
Figure 131: East Asia Market Value (US$ million) Analysis by Country, 2017 to 2032
Figure 132: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 133: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 134: East Asia Market Value (US$ million) Analysis by Product Type, 2017 to 2032
Figure 135: East Asia Market Value Share (%) and BPS Analysis by Product Type, 2022 to 2032
Figure 136: East Asia Market Y-o-Y Growth (%) Projections by Product Type, 2022 to 2032
Figure 137: East Asia Market Value (US$ million) Analysis by Synthesis, 2017 to 2032
Figure 138: East Asia Market Value Share (%) and BPS Analysis by Synthesis, 2022 to 2032
Figure 139: East Asia Market Y-o-Y Growth (%) Projections by Synthesis, 2022 to 2032
Figure 140: East Asia Market Value (US$ million) Analysis by Application, 2017 to 2032
Figure 141: East Asia Market Value Share (%) and BPS Analysis by Application, 2022 to 2032
Figure 142: East Asia Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032
Figure 143: East Asia Market Value (US$ million) Analysis by Dosage Form, 2017 to 2032
Figure 144: East Asia Market Value Share (%) and BPS Analysis by Dosage Form, 2022 to 2032
Figure 145: East Asia Market Y-o-Y Growth (%) Projections by Dosage Form, 2022 to 2032
Figure 146: East Asia Market Attractiveness by Product Type, 2022 to 2032
Figure 147: East Asia Market Attractiveness by Synthesis, 2022 to 2032
Figure 148: East Asia Market Attractiveness by Application, 2022 to 2032
Figure 149: East Asia Market Attractiveness by Dosage Form, 2022 to 2032
Figure 150: East Asia Market Attractiveness by Country, 2022 to 2032
Figure 151: Oceania Market Value (US$ million) by Product Type, 2022 to 2032
Figure 152: Oceania Market Value (US$ million) by Synthesis, 2022 to 2032
Figure 153: Oceania Market Value (US$ million) by Application, 2022 to 2032
Figure 154: Oceania Market Value (US$ million) by Dosage Form, 2022 to 2032
Figure 155: Oceania Market Value (US$ million) by Country, 2022 to 2032
Figure 156: Oceania Market Value (US$ million) Analysis by Country, 2017 to 2032
Figure 157: Oceania Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 158: Oceania Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 159: Oceania Market Value (US$ million) Analysis by Product Type, 2017 to 2032
Figure 160: Oceania Market Value Share (%) and BPS Analysis by Product Type, 2022 to 2032
Figure 161: Oceania Market Y-o-Y Growth (%) Projections by Product Type, 2022 to 2032
Figure 162: Oceania Market Value (US$ million) Analysis by Synthesis, 2017 to 2032
Figure 163: Oceania Market Value Share (%) and BPS Analysis by Synthesis, 2022 to 2032
Figure 164: Oceania Market Y-o-Y Growth (%) Projections by Synthesis, 2022 to 2032
Figure 165: Oceania Market Value (US$ million) Analysis by Application, 2017 to 2032
Figure 166: Oceania Market Value Share (%) and BPS Analysis by Application, 2022 to 2032
Figure 167: Oceania Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032
Figure 168: Oceania Market Value (US$ million) Analysis by Dosage Form, 2017 to 2032
Figure 169: Oceania Market Value Share (%) and BPS Analysis by Dosage Form, 2022 to 2032
Figure 170: Oceania Market Y-o-Y Growth (%) Projections by Dosage Form, 2022 to 2032
Figure 171: Oceania Market Attractiveness by Product Type, 2022 to 2032
Figure 172: Oceania Market Attractiveness by Synthesis, 2022 to 2032
Figure 173: Oceania Market Attractiveness by Application, 2022 to 2032
Figure 174: Oceania Market Attractiveness by Dosage Form, 2022 to 2032
Figure 175: Oceania Market Attractiveness by Country, 2022 to 2032
Figure 176: MEA Market Value (US$ million) by Product Type, 2022 to 2032
Figure 177: MEA Market Value (US$ million) by Synthesis, 2022 to 2032
Figure 178: MEA Market Value (US$ million) by Application, 2022 to 2032
Figure 179: MEA Market Value (US$ million) by Dosage Form, 2022 to 2032
Figure 180: MEA Market Value (US$ million) by Country, 2022 to 2032
Figure 181: MEA Market Value (US$ million) Analysis by Country, 2017 to 2032
Figure 182: MEA Market Value Share (%) and BPS Analysis by Country, 2022 to 2032
Figure 183: MEA Market Y-o-Y Growth (%) Projections by Country, 2022 to 2032
Figure 184: MEA Market Value (US$ million) Analysis by Product Type, 2017 to 2032
Figure 185: MEA Market Value Share (%) and BPS Analysis by Product Type, 2022 to 2032
Figure 186: MEA Market Y-o-Y Growth (%) Projections by Product Type, 2022 to 2032
Figure 187: MEA Market Value (US$ million) Analysis by Synthesis, 2017 to 2032
Figure 188: MEA Market Value Share (%) and BPS Analysis by Synthesis, 2022 to 2032
Figure 189: MEA Market Y-o-Y Growth (%) Projections by Synthesis, 2022 to 2032
Figure 190: MEA Market Value (US$ million) Analysis by Application, 2017 to 2032
Figure 191: MEA Market Value Share (%) and BPS Analysis by Application, 2022 to 2032
Figure 192: MEA Market Y-o-Y Growth (%) Projections by Application, 2022 to 2032
Figure 193: MEA Market Value (US$ million) Analysis by Dosage Form, 2017 to 2032
Figure 194: MEA Market Value Share (%) and BPS Analysis by Dosage Form, 2022 to 2032
Figure 195: MEA Market Y-o-Y Growth (%) Projections by Dosage Form, 2022 to 2032
Figure 196: MEA Market Attractiveness by Product Type, 2022 to 2032
Figure 197: MEA Market Attractiveness by Synthesis, 2022 to 2032
Figure 198: MEA Market Attractiveness by Application, 2022 to 2032
Figure 199: MEA Market Attractiveness by Dosage Form, 2022 to 2032
Figure 200: MEA Market Attractiveness by Country, 2022 to 2032
FMI projects the global High Potency API Contract Manufacturing market to expand at a 7% value CAGR by 2032
The global high potency API contract manufacturing market is estimated at a market value of USD 8 Billion
The global High Potency API Contract Manufacturing market is expected to garner a market value of USD 16 Billion
Piramal Pharma Solutions, Lonza, Catalent, Inc., VxP Pharma, Inc., Pfizer CentreOne, Gentec Pharmaceutical Group, AbbVie, Aurigene Pharmaceutical Services Ltd., CordenPharma International and Curia Global, Inc., are some prominent High Potency API Contract Manufacturing manufacturers.
The oncology segment is expected to hold the largest market share for High Potency API Contract Manufacturing in the forecast period 2022 to 2032.
Explore Similar Insights
High Potency API Contract Manufacturing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
